Stavros Niarchos Foundation Complex Joint Reconstruction Center Fellowship Ivan De Martino, MD As the Stavros Niarchos Foundation Complex Joint Reconstruction Center Clinical Fellow, Dr. Ivan De Martino participated extensively in groundbreaking research and the dissemination of findings to the medical community. Dr. De Martino published several papers in the Journal of Arthroplasty and in International Orthopaedics, and has co-written three chapters on hip and knee replacement as well as robotic-assisted surgery. Following the fellowship, Dr. De Martino joined the Catholic University of the Sacred Heart in Rome, Italy, as an Assistant Professor.
Stavros Niarchos Foundation Complex Joint Reconstruction Center Fellowship As the Stavros Niarchos Foundation Complex Joint Reconstruction Center Research Fellow, Dr. Michael-Alexander Malahias has focused his investigations on revision surgery for patients with acetabular bone loss (severe bone loss in the hip socket). Dr. Malahias’ research findings have been submitted for presentation at the American Academy of Orthopaedic Surgeons/American Association of Hip and Knee Surgeons (AAOS/AAHKS) conferences, and they will subsequently be submitted for publication. He has also published two manuscripts on total knee replacement surgery—one in the Journal of Arthroplasty and the other in The Knee. Following his training at HSS, he will continue as an Arthroplasty Clinical Fellow at the University of Toronto, St. Michael’s Hospital in Canada.
Robert and Gillian Steel Fellowship in Musculoskeletal Research Inez Rogatsky, PhD Dr. Inez Rogatsky is a Senior Scientist at HSS in the Arthritis and Tissue Degeneration Program, a member of the David Z. Rosensweig Genomics Research Center, and a Professor at Weill Cornell Medical College. A portion of her studies aim to improve glucocorticoid steroids, frontline drugs used to combat autoimmune and inflammatory diseases. Dr. Rogatsky is exploring the molecular mechanisms by which glucocorticoid steroids act on the immune system. Understanding this interaction may enable scientists to selectively channel glucocorticoids exclusively to the specific inflammatory cells of the immune system while sparing other cell types, so that excessive exposure to these drugs no longer causes harmful side effects, such as metabolic syndrome, type II diabetes, osteoporosis, muscular dystrophy, and vascular hypertension.
Advancing the Frontiers of Medicine | 17
2019- 2020 FELLOWS HIPS
Michael-Alexander Malahias, MD